COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
Colchicine study #8 of 9
1/27 Late treatment study
Tardif et al., medRxiv, doi:10.1101/2021.01.26.21250494 (Preprint)
Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19
Source   PDF   Share   Tweet
RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.

Tardif et al., 1/27/2021, Double Blind Randomized Controlled Trial, Canada, North America, preprint, 41 authors.
risk of death, 43.9% lower, RR 0.56, p = 0.30, treatment 5 of 2235 (0.2%), control 9 of 2253 (0.4%), odds ratio converted to relative risk.
risk of mechanical ventilation, 46.8% lower, RR 0.53, p = 0.09, treatment 11 of 2235 (0.5%), control 21 of 2253 (0.9%), odds ratio converted to relative risk.
risk of hospitalization, 20.0% lower, RR 0.80, p = 0.07, treatment 101 of 2235 (4.5%), control 128 of 2253 (5.7%), odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 9 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to cover all people and all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images